IP Library › Granted Patent US 7,101,559
Granted Patent B2
US 7,101,559 · App. 10/455,000 · Granted Sep 5, 2006

Immunomodulatory protein and useful embodiments thereof

Assignee: Viron Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,101,559
App. No.
10/455,000
Granted
Sep 5, 2006
Kind
B2
Abstract

The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immune-related diseases.

Claims (19)

1. A purified nucleic acid molecule derived from the Yaba Monkey Tumor Virus having at least 99% nucleic acid sequence identity to SEQ ID NO:1, wherein said nucleic acid molecule encodes a polypeptide that modulates cytokine function.

2. The nucleic acid molecule of claim 1 , wherein said nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:1.

3. The nucleic acid molecule of claim 1 , wherein said nucleic acid molecule consists of SEQ ID NO:1.

4. A nucleic acid molecule comprising a sequence complementary to a nucleic acid sequence having at least 99% identity to SEQ ID NO:1.

5. The nucleic acid molecule of claim 1 , wherein each T is replaced with a U.

6. A vector comprising the nucleic acid molecule of claim 1 .

7. The vector of claim 6 , wherein said nucleic acid molecule is positioned for expression.

8. The vector of claim 6 , wherein said nucleic acid molecule is under the control of an inducible promoter.

9. The vector of claim 6 , wherein said vector is suitable for expression in a mammalian cell.

10. A pharmaceutical composition comprising the nucleic acid molecule of claim 1 formulated in a pharmaceutically acceptable carrier in an amount sufficient to treat an immune disorder or inflammation when administered to a cell of a subject.

11. The purified nucleic acid molecule of claim 1 , wherein said nucleic acid molecule encodes a Yaba Monkey Tumor Virus polypeptide.

12. The purified nucleic acid molecule of claim 11 , wherein said nucleic acid molecule encodes a polypeptide comprising an amino acid sequence having at least 99% amino acid sequence identity to SEQ ID NO:2.

13. The purified nucleic acid molecule of claim 12 , wherein said nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

14. The purified nucleic acid molecule of claim 13 , wherein said nucleic acid molecule encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

15. A vector comprising the nucleic acid molecule of claim 11 .

16. The vector of claim 15 , wherein said nucleic acid molecule is positioned for expression.

17. The vector of claim 15 , wherein said nucleic acid molecule is under the control of an inducible promoter.

18. The vector of claim 15 , wherein said vector is suitable for expression in a mammalian cell.

19. A vector comprising the nucleic acid molecule of claim 13 .

Assignments (9)
SECURITY AGREEMENT Recorded Jul 8, 2008
From: EASTERN TECHNOLOGY SEED INVESTMENT FUND LIMITED PARTNERSHIP; TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG; ROYAL BANK OF CANADAD; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0109 →
SECURITY AGREEMENT Recorded Jul 8, 2008
From: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG; ROYAL BANK OF CANADAD; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0124 →
SECURITY AGREEMENT Recorded Jul 8, 2008
From: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0135 →
SECURITY AGREEMENT Recorded Jul 8, 2008
From: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0143 →
SECURITY AGREEMENT Recorded Jul 12, 2004
From: VIRON THERAPEUTICS INC.
To: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
Reel/Frame 016256/0117 →
SECURITY INTEREST Recorded Dec 9, 2003
From: VIRON THERAPEUTICS INC.
To: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
Reel/Frame 014754/0221 →
SECURITY INTEREST Recorded Dec 9, 2003
From: VIRON THERAPEUTICS INC.
To: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG (AS ASSIGNEE OF NOVARTIS INTERNATIONAL AG); ROYAL BANK OF CANADA; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
Reel/Frame 014754/0266 →
SECURITY INTEREST Recorded Dec 8, 2003
From: VIRON THERAPEUTICS INC.
To: EASTERN TECHNOLOGY SEED INVESTMENT FUND LIMITED PARTNERSHIP; TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG (AS ASSIGNEE OF NOVARTIS INTERNATIONAL AG); ROYAL BANK OF CANADA; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
Reel/Frame 014754/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2003
From: MCFADDEN, GRANT; LUCAS, ALEXANDRA; LI, XING
To: VIRON THERAPEUTICS, INC.
Reel/Frame 014670/0138 →
Continuity (3)
Continuation In Part PCTCA010173400 · Dec 4, 2001
Provisional Application 6025114700 · Dec 4, 2000
Related Publication 20040038203A1 · Feb 26, 2004